Apellis Pharmaceuticals (APLS): next trial readout expected around 2027-06-25
$APLS · Apellis Pharmaceuticals, Inc.Trials that could report in the next 12 months: 1BiopharmaCTG
Catalyst timeline
Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything APLS is running — see methodology.
- 2027-06-25in 44wA Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study t… | Phase 2 | Recruitingstill enrolling patients | 2027-06-25 | NCT07215390 |
| A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturn… | Phase 2 | Recruitingstill enrolling patients | NCT04901936 | |
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate … | Phase 3 | Active Not Recruitingenrolled, still running | NCT05809531 | |
| Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults a… | Phase 3 | Suspendedpaused | NCT07020832 | |
| A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental … | Phase 2 | Suspendedpaused | NCT07213960 |
Status-change history
Every ClinicalTrials.gov change recorded for APLS's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is APLS's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is APLS's lead program in?
Phase 3 — active not recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.